• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血管紧张素II 1型受体阻滞剂、钙通道阻滞剂和氢氯噻嗪联合治疗高血压患者的疗效与安全性

Efficacy and Safety of Combination Therapy Consisting of Angiotensin II Type 1 Receptor Blocker, Calcium Channel Blocker and Hydrochlorothiazide in Patients With Hypertension.

作者信息

Shiga Yuhei, Miura Shin-Ichiro, Motozato Kota, Yoshimine Yuka, Norimatsu Kenji, Arimura Tadaaki, Koyoshi Rie, Morii Joji, Kuwano Takashi, Inoue Ken, Shirotani Tetsuro, Fujisawa Kazuaki, Matsunaga Eiyu, Saku Keijiro

机构信息

Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; Inoue Hospital, Fukuoka, Japan; Shirotani Hospital, Fukuoka, Japan.

Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.

出版信息

J Clin Med Res. 2017 Feb;9(2):98-103. doi: 10.14740/jocmr2838w. Epub 2016 Dec 31.

DOI:10.14740/jocmr2838w
PMID:28090225
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5215013/
Abstract

BACKGROUND

Many patients continue to have high blood pressure (BP) even after treatment with high-dose (H)-angiotensin II type 1 receptor blocker (ARB)/calcium channel blocker (CCB) or middle-dose (M)-ARB/CCB/hydrochlorothiazide (HCTZ).

METHODS

Thirty-two hypertensive patients who had the use of H-ARB/CCB or M-ARB/CCB/HCTZ were enrolled in this study. We applied a changeover with a switch to H-ARB (telmisartan 80 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day)/HCTZ (12.5 mg/day).

RESULTS

Systolic BP (SBP) and diastolic BP (DBP) were significantly decreased in all patients and in the H-ARB/CCB and M-ARB/CCB/HCTZ groups after 3 months. Percentage (%) of patients who reached the target BP after 3 months (72%) in all patients was significantly higher than that at 0 months (19%). There were no serious adverse effects in any of the patients.

CONCLUSIONS

Combination therapy with H-ARB/CCB/HCTZ was associated with a significant reduction of BP.

摘要

背景

许多患者即使在接受大剂量（H）-1型血管紧张素II受体阻滞剂（ARB）/钙通道阻滞剂（CCB）或中剂量（M）-ARB/CCB/氢氯噻嗪（HCTZ）治疗后仍患有高血压（BP）。

方法

本研究纳入了32例使用H-ARB/CCB或M-ARB/CCB/HCTZ的高血压患者。我们采用了换药方案，改为使用H-ARB（替米沙坦80毫克/天）/CCB（氨氯地平5毫克/天或硝苯地平控释片40毫克/天）/HCTZ（12.5毫克/天）。

结果

3个月后，所有患者以及H-ARB/CCB组和M-ARB/CCB/HCTZ组的收缩压（SBP）和舒张压（DBP）均显著降低。所有患者中3个月后达到目标血压的患者百分比（72%）显著高于0个月时（19%）。所有患者均未出现严重不良反应。

结论

H-ARB/CCB/HCTZ联合治疗可显著降低血压。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a7/5215013/c5b900fb2f33/jocmr-09-098-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a7/5215013/9d40d11e2656/jocmr-09-098-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a7/5215013/119892fae186/jocmr-09-098-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a7/5215013/c5b900fb2f33/jocmr-09-098-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a7/5215013/9d40d11e2656/jocmr-09-098-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a7/5215013/119892fae186/jocmr-09-098-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4a7/5215013/c5b900fb2f33/jocmr-09-098-g003.jpg

相似文献

1
Efficacy and Safety of Combination Therapy Consisting of Angiotensin II Type 1 Receptor Blocker, Calcium Channel Blocker and Hydrochlorothiazide in Patients With Hypertension.血管紧张素II 1型受体阻滞剂、钙通道阻滞剂和氢氯噻嗪联合治疗高血压患者的疗效与安全性
J Clin Med Res. 2017 Feb;9(2):98-103. doi: 10.14740/jocmr2838w. Epub 2016 Dec 31.
2
Efficacy and effects on lipid metabolism of combination treatment with losartan + hydrochlorothiazide versus losartan + amlodipine: a 48-week prospective, multicenter, randomized, open-label trial.氯沙坦联合氢氯噻嗪与氯沙坦联合氨氯地平治疗的疗效及对血脂代谢的影响：一项 48 周前瞻性、多中心、随机、开放标签试验。
Clin Ther. 2013 Apr;35(4):461-73. doi: 10.1016/j.clinthera.2013.02.021. Epub 2013 Mar 13.
3
Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis.固定剂量联合治疗的血压反应：通过个体水平荟萃分析比较氢氯噻嗪与氨氯地平。
J Hypertens. 2013 Aug;31(8):1692-701. doi: 10.1097/HJH.0b013e32836157be.
4
Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.氨氯地平/奥美沙坦±氢氯噻嗪治疗钙通道阻滞剂或血管紧张素 II 受体阻滞剂单药治疗控制不佳患者的疗效。
Adv Ther. 2012 Jun;29(6):508-23. doi: 10.1007/s12325-012-0030-z. Epub 2012 Jul 4.
5
Visit-to-Visit Variability and Seasonal Variation in Blood Pressure With Single-Pill Fixed-Dose Combinations of Angiotensin II Receptor Blocker/Calcium Channel Blocker and Angiotensin II Receptor Blocker/Diuretic in Hypertensive Patients.高血压患者使用血管紧张素II受体阻滞剂/钙通道阻滞剂单片固定剂量复方制剂和血管紧张素II受体阻滞剂/利尿剂时血压的逐次就诊变异性和季节性变化
J Clin Med Res. 2015 Oct;7(10):802-6. doi: 10.14740/jocmr2292w. Epub 2015 Aug 23.
6
Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients.利尿剂或钙通道阻滞剂联合血管紧张素受体阻滞剂对高血压患者舒张功能的影响。
Circ J. 2016;80(2):426-34. doi: 10.1253/circj.CJ-15-0815. Epub 2015 Dec 25.
7
S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.氨氯地平单药治疗无效的高血压患者中，左旋氨氯地平联合氯噻酮与左旋氨氯地平联合替米沙坦的疗效比较：一项随机对照试验的研究方案
Trials. 2018 Jun 20;19(1):324. doi: 10.1186/s13063-018-2636-1.
8
Meta-analysis of the efficacy and safety of adding an angiotensin receptor blocker (ARB) to a calcium channel blocker (CCB) following ineffective CCB monotherapy.在钙通道阻滞剂（CCB）单药治疗无效后加用血管紧张素受体阻滞剂（ARB）的疗效和安全性的荟萃分析。
J Thorac Dis. 2015 Dec;7(12):2243-52. doi: 10.3978/j.issn.2072-1439.2015.12.39.
9
Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.高血压慢性肾脏病联合治疗耐受性和疗效的前瞻性随机研究：PROTECT-CKD研究结果
Clin Exp Nephrol. 2015 Oct;19(5):925-32. doi: 10.1007/s10157-015-1091-5. Epub 2015 Feb 14.
10
Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) Study.氯沙坦 - 氢氯噻嗪复方片剂治疗血管紧张素II受体拮抗剂治疗控制不佳的高血压患者的疗效和安全性：爱知高血压联合治疗研究（ARCH研究）
Intern Med. 2012;51(10):1167-75. doi: 10.2169/internalmedicine.51.6297. Epub 2012 May 15.

本文引用的文献

1
Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.系统评价替米沙坦对合并胰岛素抵抗或糖尿病的高血压患者胰岛素敏感性的影响。
J Clin Pharm Ther. 2012 Jun;37(3):319-27. doi: 10.1111/j.1365-2710.2011.01295.x. Epub 2011 Aug 17.
2
The therapeutic importance of home blood pressure assessment and combination antihypertensive therapy for achieving target blood pressure control: Ibaraki hypertension assessment trial.家庭血压评估和联合降压治疗在实现目标血压控制方面的治疗重要性：茨城县高血压评估试验。
Hypertens Res. 2010 Dec;33(12):1264-71. doi: 10.1038/hr.2010.175. Epub 2010 Oct 7.
3
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009).
日本高血压学会高血压管理指南（JSH 2009）
Hypertens Res. 2009 Jan;32(1):3-107.
4
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.替米沙坦在降低糖尿病肾病患者蛋白尿方面比氯沙坦更有效。
Kidney Int. 2008 Aug;74(3):364-9. doi: 10.1038/ki.2008.204. Epub 2008 May 21.
5
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).2007年动脉高血压管理指南：欧洲高血压学会（ESH）和欧洲心脏病学会（ESC）动脉高血压管理特别工作组制定
J Hypertens. 2007 Jun;25(6):1105-87. doi: 10.1097/HJH.0b013e3281fc975a.
6
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.阿利吉仑抑制肾素与氢氯噻嗪联合使用时可提供额外的降压疗效。
J Hypertens. 2007 Jan;25(1):217-26. doi: 10.1097/HJH.0b013e3280103a6b.
7
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.盎格鲁-斯堪的纳维亚心脏结局试验-降压分支（ASCOT-BPLA）：氨氯地平降压方案按需加用培哚普利与阿替洛尔按需加用苄氟噻嗪预防心血管事件的多中心随机对照试验
Lancet. 2005;366(9489):895-906. doi: 10.1016/S0140-6736(05)67185-1.
8
Diuretics in the LIFE study.LIFE研究中的利尿剂
Lancet. 2004;364(9432):413; author reply 413-4. doi: 10.1016/S0140-6736(04)16755-X.
9
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.替米沙坦作为具有选择性过氧化物酶体增殖物激活受体γ调节活性的独特血管紧张素II受体拮抗剂的鉴定。
Hypertension. 2004 May;43(5):993-1002. doi: 10.1161/01.HYP.0000123072.34629.57. Epub 2004 Mar 8.